Jose Manuel Zozaya
Overview
Explore the profile of Jose Manuel Zozaya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burgui C, San Miguel R, Goni-Esarte S, Juanbeltz R, Uriz-Otano J, Reparaz J, et al.
Postgrad Med
. 2022 Oct;
135(4):352-360.
PMID: 36305320
Objectives: Second-generation direct-acting antivirals (DAAs) have shown high efficacy in the treatment of chronic hepatitis C virus (HCV) infections in clinical trials. This study aimed to estimate the effectiveness in...
2.
Rodriguez C, Elosua A, Prieto C, Perez E, Irisarri R, Campillo A, et al.
Gastroenterol Hepatol
. 2021 Feb;
45(1):1-8.
PMID: 33545242
Introduction: Knowing the natural history of ulcerative colitis (UC) is essential to understand the course of the disease, assess the impact of different treatment strategies and identify poor prognostic factors....
3.
Burgui C, Martin C, Juanbeltz R, San Miguel R, Martinez-Baz I, Zozaya J, et al.
Rev Esp Enferm Dig
. 2020 Jun;
112(7):525-531.
PMID: 32515981
Background: hepatitis C virus (HCV) antibody tests have been performed since the 90s, although HCV-RNA (viral load) determination was not always performed. Some of these patients may be actively infected...
4.
Vila J, Carrascosa J, Fernandez-Urien I, Yeaton P, Gonzalez G, Aburruza L, et al.
Endoscopy
. 2020 Jun;
53(1):E29-E30.
PMID: 32483790
No abstract available.
5.
Goni Esarte S, Juanbeltz R, Zozaya J, Uriz J, Castilla J, Herrero J
Gastroenterol Hepatol
. 2020 Mar;
43(5):248-255.
PMID: 32192765
Introduction: There is little information on whether direct-acting antiviral (DAA) treatment can improve liver fibrosis or change glucose and lipid profile in patients with chronic hepatitis C (CHC). We aimed...
6.
Sousa J, Vergara M, Pulido F, Antolin G, Hijona L, Carnicer F, et al.
PLoS One
. 2019 Nov;
14(11):e0225061.
PMID: 31714950
Aim: We describe the effectiveness and safety of the interferon-free regimen ombitasvir/paritaprevir/ritonavir plus dasabuvir with or without ribavirin (OBV/PTV/r ± DSV ± RBV) in a nationwide representative sample of the...
7.
Goni Esarte S, Juanbeltz R, Martinez-Baz I, Castilla J, San Miguel R, Herrero J, et al.
Rev Esp Enferm Dig
. 2019 May;
111(6):445-452.
PMID: 31066286
Background And Aim: new direct-acting antivirals (DAAs) achieve high and sustained virological response (SVR) rates, although the long-term effect on patient health-related quality of life (HRQoL) is unknown. This study...
8.
Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain
Juanbeltz R, Perez-Garcia A, Aguinaga A, Martinez-Baz I, Casado I, Burgui C, et al.
PLoS One
. 2018 Dec;
13(12):e0208554.
PMID: 30513107
Background: The World Health Organization set targets to eliminate hepatitis C virus (HCV) infection through detection and treatment of all cases by 2030. This study aimed to describe the progress...
9.
Juanbeltz R, Goni Esarte S, Uriz-Otano J, Martinez Echeverria A, Elizalde I, Zozaya J, et al.
Postgrad Med
. 2017 Mar;
129(4):476-483.
PMID: 28343408
Objectives: Direct acting antivirals (DAA) are extremely effective to treat chronic hepatitis C. The aim of this study was to evaluate, by using objective variables, the safety of DAA combinations...
10.
Bolado F, Prieto C, Vila J, Fernandez-Urien I, Forga L, Zozaya J
Pancreas
. 2016 Dec;
46(1):102-105.
PMID: 27984488
Objectives: Previous studies have shown changes in the pancreas of type 1 diabetic (T1-DM) patients, similar to those present in patients with chronic pancreatitis. Our aim was to analyze the...